Reviewed listing: NASDAQ:BTSG · Analysis dated Nov 03, 2026
How does the company make money?
BrightSpring provides medications, including specialty and infusion drugs, and delivers home health and therapy services. Its customers include patients, care facilities, and health care providers; payment comes mainly through insurance and government programs.
What supports the business?
In the third quarter of 2026, income from continuing operations rose to 101 million USD, compared with 37 million USD in the year-ago quarter. Revenue also grew significantly.
What could improve?
Higher revenue from specialty drugs and health services could further strengthen earnings. For that to happen, growth must also show up in net income after costs and interest.
How is the stock price assessed?
This assessment refers to the analysis and its quoted price shown here. It is not a live quote or a personal recommendation to buy.
At 66.26 USD, the stock looks expensive: The price is about 42 times earnings per share annualized from the first nine months. This annualized figure is only a rough guide, not an earnings forecast.
What is the main risk?
Low profit margins leave little cushion if labor or drug costs rise or reimbursement rates fall. Also, the adjusted metric highlighted by the company does not include costs such as stock-based compensation.
What is the overall assessment?
BrightSpring is growing, earning significantly more than in the year-ago quarter, and has reduced its debt metric. At the specified price, however, the stock requires strong results to continue, while thin profit margins and cost risks leave little room for error; as a result, the overall risk-reward balance is not attractive right now.
Continue exploring this stock in your account
A free Marqora account gives you the detailed analysis with further evidence and lets you compare and save stocks. Your selected stock is kept when you sign in or register.
Open the full analysis in a free account →
Already have an account? Sign in